Actinium Pharmaceuticals
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
100 Park Ave Fl 23, New York, New York, ...Phone Number
(646) 677-3870Website
www.actiniumpharma.comRevenue
$35.1 MillionStock Symbol
ATNMIndustry
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. specializes in targeted radiotherapies aimed at addressing unmet medical needs in oncology. Their product pipeline includes Actimab-A, a therapeutic for relapsed/refractory acute myeloid leukemia, and ATNM-400, a first-in-class radiotherapy for various cancers. The company focuses on innovative treatments utilizing Actinium-225 technology for targeted conditioning and radiotherapy. Their intended clients include patients suffering from advanced cancers such as mCRPC, NSCLC, and breast cancer.Explore more
Actinium Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Actinium Pharmaceuticals
Compare insights from companies similar to Actinium Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$132.7M
51-200
Public
$547.1M
1994
JB
Jennifer BuellPresident and CEO of MiNK Therapeutics, Chairman, Executive Council At Agenus
Actinium Pharmaceuticals Tech Stack
A closer look at the technologies used by Actinium Pharmaceuticals
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Actinium Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Actinium Pharmaceuticals, Inc. specializes in targeted radiotherapies aimed at addressing unmet medical needs in oncology. Their product pipeline includes Actimab-A, a therapeutic for relapsed/refractory acute myeloid leukemia, and ATNM-400, a first-in-class radiotherapy for various cancers. The company focuses on innovative treatments utilizing Ac... Read More
